The Australian Drosophila Transgenic Facility (ADTF) achieves a milestone with inaugural order fulfilment to unveil the molecular basis of disease.
The Australian Drosophila Transgenic Facility (ADTF), supported by Phenomics Australia and the Peter MacCallum Cancer Centre, and co-led by Phenomics Australia Scientific Leader Prof Kieran Harvey and A/Prof Louise Cheng, offers specialised microinjection services for generating transgenic strains of the vinegar fly Drosophila melanogaster.
The mission of the ADTF is to enhance research capabilities for Australian scientists by providing a more cost effective and streamlined approach to the generation of transgenic Drosophila strains.
From the inception of your project to the delivery of transgenic Drosophila strains, the ADTF facility is here to support your research endeavours.
“Transgenic studies are essential for animal models such as Drosophila. The Australian Drosophila Transgenic Facility in Peter Mac made everything easy and efficient from order, project updates and delivery. What used to take two to three months now takes a few weeks to receive transgenic flies. This will not only enhance our productivities, but also change the way we do fly research in Australia. We start thinking more creative now.” Dr Rippei Hayashi Group leader of the Transposon Defence and Animal Development Lab at the John Curtin School of Medical Research (JCSMR) said.
The ADTF boasts cutting-edge microinjection equipment, ensuring the consistent and efficient production of a diverse array of transgenic Drosophila strains. This state-of-the-art facility offers Australian research centers significant advantages, capitalizing on economies of scale and elevating the overall productivity of their researchers.
ACDT actively fosters collaboration among local researchers, augmenting their appeal to international counterparts. By substantially reducing entry costs and technical barriers associated with Drosophila research, it facilitates a seamless transition for investigators currently immersed in other experimental systems. Moreover, the facility contributes to the expansion of Australia’s research skill set, creating valuable employment and training opportunities in the process.
With an established track record and reputation for excellence, Phenomics Australia In Vivo Genome Engineering and Disease Modelling team uses techniques such as CRISPR-mediated mutagenesis, classical gene targeting, and transgenesis to create optimal tools for your research delivering a comprehensive service in genome modification. To meet the high demand for this platform, Phenomics Australia offers genome editing services through five nodes across Australia, operating at Monash, ANU, WEHI, SAHMRI and PeterMac.